According to the official website of the National Healthcare Security Administration, in recent times, it has been discovered in some regions that designated retail pharmacies (hereinafter referred to as "designated pharmacies") adopt "yin-yang pricing" (discriminatory pricing) behavior towards medical insurance non insurance patients, that is, the price of identical drugs sold to medical insurance patients is higher than that of non insurance patients. According to legal requirements such as the Price Law of the People's Republic of China and the Drug Administration Law of the People's Republic of China, designated pharmacies are suspected of price fraud by selling drugs at high prices to insured patients for profit. At the same time, they violate the management requirement in the medical insurance service agreement of designated pharmacies that "unfair and discriminatory prices shall not be imposed on medical insurance insured persons", and should be seriously investigated and dealt with. To further strengthen monitoring and disposal, the National Healthcare Security Administration has issued a notice on further strengthening the monitoring and disposal of "yin-yang prices" of drugs in designated retail pharmacies. The specific content is as follows. One is to pay close attention to the clues of the "yin-yang price" issue in designated pharmacies. Medical insurance departments in various regions should fully recognize the problem of the "yin-yang price" behavior of designated pharmacies infringing on the rights and interests of insured persons, and the adverse effects of illegal use of medical insurance funds causing fund losses. Further enhance risk prevention awareness. Strengthen the management of drug prices in designated pharmacies, incorporate the "yin-yang price" behavior of designated pharmacies into key monitoring items, and clarify the requirements for handling "yin-yang price" issues. Organize designated pharmacies within the jurisdiction to conduct self-examination and self correction of drug "yin-yang pricing" issues, and promptly rectify the problem of discriminatory pricing towards insured persons. Proactively screen for clues related to key varieties. Focusing on drugs with high settlement amounts or significant price differences among designated pharmacies in various regions, we will screen for drug varieties. Through screening medical insurance settlement data and systematically sorting out recent public complaints and public opinion feedback, we will form clues to the "yin-yang price" problem of drugs in designated pharmacies in the local area. Fully mobilize social supervision forces. The implementation of "yin-yang pricing" in designated pharmacies is an illegal and irregular use of medical insurance funds. Local governments can follow the reporting and reward mechanism for illegal and irregular use of medical security funds to encourage the general public to actively provide relevant problem clues to the medical insurance department and participate in the governance of "yin-yang pricing" issues in designated pharmacies. The second is to seriously investigate and handle the issue of "yin-yang prices". Medical insurance departments in various regions should effectively fulfill their main responsibilities, strengthen coordination and linkage with market supervision departments, and enhance on-site inspections and reporting verification. Strengthen data screening and on-site verification. Medical insurance departments in various regions should use medical insurance settlement data to organize on-site key inspections of designated pharmacies that have found abnormal drug price data uploads or clues of "yin-yang price" issues reported by the public, combined with inventory data, self payment purchase records, video surveillance, etc. of designated pharmacies. Focus on investigating designated pharmacies that discriminate against insured and non insured individuals due to different settlement methods, or only sell drugs to non insured individuals through disguised price reductions such as additional rebates, discounts, and full discounts. Strengthen the management of designated pharmacy agreements. Designated pharmacies are required not to impose unfair or discriminatory prices on medical insurance insured persons, and not to sell drugs at prices higher than those of non insured persons. They must strictly comply with the relevant agreement handling requirements for the "yin-yang price" behavior of drugs in the agreement. For designated pharmacies that violate the medical insurance service agreement by implementing "yin-yang pricing", depending on the severity of the situation and the rectification situation, measures such as interviewing the main person in charge, suspending medical insurance settlement, refusing to pay or recovering paid medical insurance funds, suspending or terminating medical insurance service agreements, and transferring to relevant departments for handling will be taken seriously to effectively safeguard the security of medical insurance funds and protect the rights and interests of the public in purchasing drugs. Include in the scope of flight inspection. For designated pharmacies where data screening, on-site verification, and public reports reveal that "yin-yang prices" involve large amounts of drugs and serious circumstances, they will be included in the scope of flight inspections. The third is to carry out regular monitoring and governance. Medical insurance departments in various regions should effectively fulfill the responsibility of drug price management of medical security departments, and regularly manage drug prices in designated pharmacies. Continuously use the drug comparison mini program. Make full use of the actual settlement price and pharmacy retail price information in the medical insurance information system, provide services such as price comparison and location navigation for designated pharmacies, form a market-oriented price comparison mechanism, facilitate the public to compare prices among surrounding pharmacies, and guide designated pharmacies to set prices fairly, reasonably, and honestly. Further promote the application of quantity price comparison index. Take the annual monitoring value of the volume price comparison index as the overall price monitoring warning line for this year. According to the management requirements of the designated pharmacy agreement, appointment reminders will be given to designated pharmacies that have not met the annual monitoring value requirements. Those who refuse price adjustments or still do not meet the requirements after adjustments will be suspended from settlement until the medical insurance service agreement is terminated. Regularly carry out verification and disposal of drug price risk varieties. Proactively monitor drug price risk varieties with high transaction settlement amounts and significant price differences in designated pharmacies, promptly verify and dispose of actual sales prices of designated pharmacies that are higher than the mode price of designated pharmacies in the province, and adopt unfair pricing practices towards non insured individuals covered by medical insurance. Guide designated pharmacies to standardize data uploading. Strengthen the standardization requirements for uploading drug price data in designated pharmacies. If there are errors, incompleteness, or inaccuracy in uploading medical insurance settlement data such as drug medical insurance codes, unit prices, and quantities in designated pharmacies, they should be handled according to the protocol management requirements of designated pharmacies and regularly reported. Remind insured individuals to pay attention to price information. Post prominent signs at designated pharmacies to remind insured persons to verify the price information of drugs with clear prices, and not to use discriminatory pricing behavior against insured persons. (New Society)